[go: up one dir, main page]

KR950704342A - 전신 염증(systemic inflammation) 및 염증성 간염(inflammatory hepatitis) 치료용 피리미딘 누클레오티드 전구체(pyrimindine nucleotide precursor) - Google Patents

전신 염증(systemic inflammation) 및 염증성 간염(inflammatory hepatitis) 치료용 피리미딘 누클레오티드 전구체(pyrimindine nucleotide precursor)

Info

Publication number
KR950704342A
KR950704342A KR1019950702327A KR19950702327A KR950704342A KR 950704342 A KR950704342 A KR 950704342A KR 1019950702327 A KR1019950702327 A KR 1019950702327A KR 19950702327 A KR19950702327 A KR 19950702327A KR 950704342 A KR950704342 A KR 950704342A
Authority
KR
South Korea
Prior art keywords
uridine
animal
administering
cytidine
pyrimidine nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019950702327A
Other languages
English (en)
Other versions
KR100315890B1 (ko
Inventor
레이드 워렌 본 보르스텔
마이클 케빈 바매트
브래들레이 엠. 힐트브랜드
Original Assignee
하비 라빈
프로-뉴런, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하비 라빈, 프로-뉴런, 인코포레이티드 filed Critical 하비 라빈
Publication of KR950704342A publication Critical patent/KR950704342A/ko
Application granted granted Critical
Publication of KR100315890B1 publication Critical patent/KR100315890B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 시티딘, 우리딘 및 오로테이트의 아실 유도체를 포함하는 피리미딘 누클레이오티드 전구체; 우리딘 포스포릴라제 억제물질 및; 상기 물질들을 패혈증이나 전신 염증에 대한 저항력 증가를 위해 사용하는 용도에 대한 것이다.

Description

전신 염증(systemic inflammation 및 염증성 간염(inflammatory hepatitis) 치료용 피리미딘 누클레오티드 전구체(pyrimindine nucleotide precursor)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (41)

  1. 치료학적으로 유효한 양의 피리미딘 누클레오드 전구체(pyrimidine nucleotide precursor)를 동물에게 투약하는 것을 특징으로 하는 전신 염증성 반응 증후군 (systemic inflammatory response syndrome)으로 인한 조직 손상의 치료 또는 예방방법.
  2. 치료학적으로 유효한 양의 피리미딘 누클테오티드 전구체를 동물에게 투약하는 것을 특징으로 하는 패형증의 치료 또는 예방법.
  3. 제2항에 있어서, 상기 피리미딘 누클레오티드 전구체가 우리딘(uridine), 시티딘(cytidine), 오로틴산(oroticacid); 또는 우리딘, 시티딘 또는 오로틴산의 아실유도체이거나; 상기 물질들의 약제학적으로 허용가능한 염임을 특징으로 하는 방법.
  4. 제3항에 있어서, 상기 우리딘의 아실 유도체가 트리아세틸우리딘(triacetyluridine)임을 특징으로 하는 방법.
  5. 제2항에 있어서, 상기 동물이 인간임을 특징으로 하는 방법.
  6. 제2항에 있어서, 우리딘 포스포릴라제(uridine Phosphorylase)의 억제물질(inhibitor)을 투약하는 단계를 더 포함함을 특징으로 하는 방법.
  7. 치료학적으로 유효한 양의 우리딘 포스포릴라제의 억제물질을 동물에게 투약하는 것을 특징으로 하는 패혈증의 치료 또는 예방법.
  8. 치료학적 시토킨(cytokine)이나 염증성 자극물질질을 투여하기 이전이나 투여하는 동안 또는 투여 이후에 치료학적으로 유효한 양의 피리미딘 누클레오티드 전구체를 동물에게 투약하는 것을 특징으로 하는 치료학적 시토킨이나 염증성 자극물질질의 독성을 감소시키는 방법.
  9. 제8항에 있어서, 상기 피리미딘 누클레오티드 전구체가 우리딘, 시티딘, 오로틴산 또는; 우리딘, 시티딘또는 오로틴산의 아실 유도체이거나, 상기 물질의 약제학적으로 허용가능한 염임을 특징으로 하는 방법.
  10. 제9항에 있어서, 상기 우리딘의 아실 유도체가 트리아세틸우리딘임을 특징으로 하는 방법.
  11. 제8항에 있어서, 상기 시토킨 또는 상기 자극물질질이 인터류킨(intcrlcukin)1, 인터류킨-2, 인터류킨 6, 종양 괴사 인자(tumor nccrosis factor), 내독소(endotoxin), 곰팡이 다당류 및 2중쇄 (doub1e-stranded)RNA로 구성된 군에서 선택된 것임을 특징으로 하는 방법.
  12. 제8항에 있어서, 우리딘 포스포릴라제의 억제물질을 투약하는 단계를 더욱 포함함을 특징으로 하는 방법.
  13. 치료학적 시토킨이나 염증성 자극물질질의 투여 이전이나, 투여 동안 또는 투여 이후에, 치료학적으로 유효한 양의 우리딘 포스포릴라제의 억제물질을 동물에게 투약하는 것을 특징으로 하는 치료학적 시토긴 또는 염증성 자극물질질의 독성을 감소시키는 방법.
  14. 제13항에 있어서, 상기 시토킨 또는 상기 자극물질이 인터류킨 1, 인터류킨-2, 인터류킨 6, 종양괴사인자, 내독소, 곰팡이 다당류 및 2중쇄 RNA로 구성된 군에서 선택된 것임을 특징으로 하는 방법.
  15. 치료학적으로 유효한 양의 치료학적 시토킨이나 염증성 자극물질을 동물에게 투여하고 상기 투여 이전이나, 투여하는 동안 또는 투여 이후에 치료학적으로 유효한 양의 피리미딘 누클레오티드 전구체를 상기 동물에게 투약하는 것을 특징으로 하는 암의 치료.
  16. 제15항에 있어서, 상기 피리미딘 누클레오티드 전구체가 우리딘, 시티딘, 오로틴산 또는; 우리딘, 시티딘 또는 오로틴산의 아실 유도체이거나; 상기 물질희 약제학적으로 허용가능한 염임을 특징으로 하는 방법.
  17. 제16항에 있어서, 상기 우리딘의 아실 유도체가 트리아세틸우리딘임을 특징으로 하는 방법.
  18. 제15항에 있어서, 상기 시토킨 또는 상기 자극물질이 인터류킨 1, 인터류킨-2, 인터류킨 6, 종양 괴사인자, 내독소, 곰팡이 다당류 및 2중쇄 RNA로 구성된 군에서 선택된 것임을 특징으로 하는 방법.
  19. 제15항에 있어서, 우리딘 포스포릴라제의 억제물질을 투약하는 단계를 더 포함함을 특징으로 하는 방법.
  20. 치료학적으로 유용한 양의 치료학적 시토킨이나 염중성 자극물질을 동물에게 투여하고 상기 투여 이전이나, 투여 동안 또는 투여 이후에 치료학적으로 유효한 양의 우리딘 포스포릴라제의 억제물질을 상기 동물에게 투약하는 것을 특징으로 하는 방법.
  21. 제20항에 있어서, 상기 시토킨이나 상기 자극물질이 인터류킨 1, 인터류킨-2, 인터류킨 6, 종양괴사인자, 내독소, 곰팡이 다당류 및 2중쇄 RNA로 구성된 군에서 선택된 것임을 특징으로 하는 방법.
  22. 우비딘, 시티딘 또는 오로틴산의 아실유도체 또는; 상기 물질들의 약제학적으로 허용가능한 염을 치료학적으로 유효한 양만큼 동물에게 투약하는 것을 특징으로 하는 염중성 간염의 치료 또는 예방법.
  23. 제22항에 있어서, 상기 우리딘의 아실 유도체가 트리아세틸우리딘임을 특징으로 하는 방법.
  24. 제22항에 있어서, 우리딘 포스포릴라제의 투약 단계를 더 포함함을 특징으로 하는 방법.
  25. 치료학적으로 유효한 양의 우리딘 포스포릴라제의 억제물질을 동물에게 투약하는 것을 특징으로 하는 염증성 간염의 치료 또는 예방법.
  26. 치료학적으로 유효한 양의 우리딘이나 시티딘을 동물에게 투약하는 것을 특징으로 하는 염증성 간염의 치료 또는 예방법.
  27. 제26항에 있어서, 2∼40g의 우리딘 또는 시티딘을 매일 투약함을 특징으로 하는 방법.
  28. 종합 비경구 영양 수액을 받고 있는 동물의 간 손상을 치료 또는 예방하기 위해, 치료학적으로 유효한 양의 피리미딘 누클레오티드 전구체를 상기 동물에게 정맥내로 투약하는 것을 특징으로 하는 방법.
  29. 제28항에 있어서, 상기 피리미딘 누클레오티드 전구체가 우리딘, 시티딘, 오로틴산 또는; 우리딘, 시티딘 또는 오로틴산의 아실 유도체이거나; 상기 물질들의 조제학적으로 허용가능한 염임을 특징으로 하는 방법.
  30. 제28항에 있어서, 2∼40g의 상기 피리미딘 누클레오티드 전구체를 매일 투약하는 것을 특징으로 하는 방법.
  31. 제28항에 있어서, 우리딘 포스포릴라제의 억제물질의 투약 단계를 더 포함함을 특징으로 하는 방법.
  32. 종합비경구 영양 수액을 받고 있는 동물의 간 손상의 치료나 예방을 위해, 우리딘 포스포릴라제의 억제 물질을 상기 동물에게 투약하는 것을 특징으로 하는 방법.
  33. 간이식을 받는 동물의 간 손상의 치료나 예방을 위해, 치료학적으로 유효한 양의 피리미딘 누클레오티드 전구체를 상기 동물에게 투약하는 것을 특징으로 하는 방법.
  34. 제33항에 있어서, 상기 피리미딘 누클레오티드 전구체가 우리딘, 시티딘, 오로틴산이거나; 우리딘, 시티딘 또는 오로틴산의 아실 유도체 또는; 상기 물질들의 조제학적으로 허용가능한 염임을 특징으로 하는 방법.
  35. 제33항에 있어서, 2∼40g의 상기 피리미딘 누클레오티드 전구체를 매일 투약함을 특징으로 하는 방법.
  36. 제33항에 있어서, 우리딘 포스포릴라제의 억제물질을 투약하는 단계를 더 포함함을 특징으로 하는 방법.
  37. 간 이식을 받는 동물의 간 손상의 치료나 예방을 위해, 우리딘 포스포릴라제의 억제물질을 상기 동물에게 투약하는 것을 특징으로 하는 방법.
  38. a)피리미딘 누클레오티드 전구체의 아실 유도체 및; b)우리딘 포스포릴라제의 억제물질을 포함하는 조성물.
  39. a)피리미딘 누클레오티드 전구체의 아실 유도체 및; b)퓨린(purine) 누클레오티드 전구체를 포함하는 조성물.
  40. 제39항에 있어서, 상기 피리미딘 누클레오티드 전구체가 우리딘, 시티딘 또는 오로테이트임을 특징으로 하는 조성물.
  41. 제39항에 있어서, 상기 퓨린 누클레오티드 전구체가 이노신(inosine), 아데노신(adenosine) 또는; 이노신이나 아데노신의 아실 유도체임을 특징으로 하는 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950702327A 1992-12-08 1993-12-01 전신염증및염증성간염치료용피리미딘누클레오티드전구체 Expired - Fee Related KR100315890B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98773092A 1992-12-08 1992-12-08
US987730 1992-12-08
PCT/US1993/011531 WO1994013687A1 (en) 1992-12-08 1993-12-01 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis

Publications (2)

Publication Number Publication Date
KR950704342A true KR950704342A (ko) 1995-11-20
KR100315890B1 KR100315890B1 (ko) 2002-06-27

Family

ID=25533509

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950702327A Expired - Fee Related KR100315890B1 (ko) 1992-12-08 1993-12-01 전신염증및염증성간염치료용피리미딘누클레오티드전구체

Country Status (14)

Country Link
EP (2) EP0679160B1 (ko)
JP (3) JPH08503699A (ko)
KR (1) KR100315890B1 (ko)
CN (2) CN1089239C (ko)
AT (1) ATE282627T1 (ko)
AU (2) AU5730594A (ko)
CA (2) CA2588495C (ko)
DE (1) DE69333699T2 (ko)
ES (1) ES2229212T3 (ko)
IL (1) IL107900A (ko)
MX (1) MX9307765A (ko)
PT (1) PT679160E (ko)
WO (1) WO1994013687A1 (ko)
ZA (1) ZA939208B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691320A (en) 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
US6329350B1 (en) 1987-10-28 2001-12-11 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
AU712679B2 (en) * 1994-07-01 1999-11-11 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
SE9701219D0 (sv) * 1997-04-04 1997-04-04 Astra Pharma Prod New compounds
US20020006913A1 (en) 1997-11-04 2002-01-17 Von Borstel Reid W. Antimutagenic compositions for treatment and prevention of photodamage to skin
SE521031C2 (sv) * 1999-05-05 2003-09-23 Srinivas Uppugunduri Nya specifika inhibitorer av akut och kronisk inflammation
WO2002100409A1 (fr) * 2001-06-11 2002-12-19 Kyowa Hakko Kogyo Co., Ltd. Compositions anti-inflammatoires et antitussives
EP3002010A1 (en) * 2014-09-30 2016-04-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Food intake, body weight and glucose metabolism regulation by modulation of P2Y6 receptor signaling
EP3169332A1 (en) * 2014-07-16 2017-05-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Food intake, body weight and glucose metabolism regulation by modulation of p2y6 receptor signaling
WO2018038599A1 (en) * 2016-08-23 2018-03-01 N.V. Nutricia Product and method for increasing uridine concentration in blood plasma
US20240390251A1 (en) 2021-10-07 2024-11-28 Yamasa Corporation Skin care composition and use thereof, and skin care composition raw material
CN114469981A (zh) * 2021-12-16 2022-05-13 中国科学院动物研究所 尿苷在促进组织器官再生或治疗和/或预防和/或缓解和/或改善组织器官损伤中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1297398A (ko) * 1969-08-06 1972-11-22
US3868451A (en) * 1971-03-30 1975-02-25 Abbott Lab Adenosine-5{40 -esters in treating angina pectoris
JPS6037182B2 (ja) * 1977-03-24 1985-08-24 日本冶金工業株式会社 耐食性にすぐれた高強度オ−ステナイトステンレス鋼
JPS6037183B2 (ja) * 1977-03-24 1985-08-24 日本冶金工業株式会社 耐食性にすぐれた高力オ−ステナイトステンレス鋼
JPS5585659A (en) * 1978-12-25 1980-06-27 Daido Steel Co Ltd Free-cutting nonmagnetic high-manganese steel
JPS58126956A (ja) * 1982-01-22 1983-07-28 Nippon Steel Corp プレス加工性の優れた高強度薄鋼板
JPS6054374B2 (ja) * 1982-04-21 1985-11-29 新日本製鐵株式会社 オ−ステナイト鋼板および鋼帯の製造方法
EP0151189B1 (en) * 1983-07-20 1990-01-31 Teijin Limited Antineoplastic agent
JPS60174797A (ja) * 1984-02-21 1985-09-09 Funai Corp Ν−アロイルチミジン誘導体ならびに抗腫瘍活性物質の毒性低下剤
KR890002033B1 (ko) * 1985-08-31 1989-06-08 한국과학기술원 최저온용 합금 및 그 제조방법
DE3856557T2 (de) * 1987-10-28 2004-06-03 Wellstat Therapeutics Corp. Acyldeoxyribonukleosid-Derivate und Verwendungen davon
EP0339075B1 (en) * 1987-10-28 1993-08-18 Pro-Neuron, Inc. Acylated uridine and cytidine and uses thereof
US4874602A (en) * 1988-02-22 1989-10-17 Paul Calabresi Reduction of the severity 3'-azido-3'-deoxythymidine-induced anemia using benzylacyclouridine
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
JP2529605B2 (ja) * 1989-10-23 1996-08-28 株式会社大塚製薬工場 免疫賦活剤
JPH03169815A (ja) * 1989-11-29 1991-07-23 Nippon Mining Co Ltd 肝臓障害予防及び治療剤
US5141943A (en) * 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives

Also Published As

Publication number Publication date
CN1211089C (zh) 2005-07-20
JP2007332144A (ja) 2007-12-27
ATE282627T1 (de) 2004-12-15
WO1994013687A1 (en) 1994-06-23
MX9307765A (es) 1994-06-30
PT679160E (pt) 2005-02-28
JPH08503699A (ja) 1996-04-23
KR100315890B1 (ko) 2002-06-27
DE69333699T2 (de) 2006-07-27
EP0679160B1 (en) 2004-11-17
AU732120B2 (en) 2001-04-12
AU5730594A (en) 1994-07-04
ZA939208B (en) 1994-08-08
EP0679160A4 (en) 1997-06-11
CA2150940C (en) 2007-08-21
EP1486210A1 (en) 2004-12-15
JP2005162757A (ja) 2005-06-23
CN1089239C (zh) 2002-08-21
AU7881398A (en) 1998-10-08
CN1309970A (zh) 2001-08-29
CA2150940A1 (en) 1994-06-23
DE69333699D1 (de) 2004-12-23
CA2588495C (en) 2009-11-17
EP0679160A1 (en) 1995-11-02
HK1004484A1 (en) 1998-11-27
CN1095268A (zh) 1994-11-23
IL107900A0 (en) 1994-05-30
IL107900A (en) 1999-12-22
ES2229212T3 (es) 2005-04-16
CA2588495A1 (en) 1994-06-23

Similar Documents

Publication Publication Date Title
KR970703776A (ko) 전신 염증 및 염증성 간염 치료용 피리미딘 누클레오티드 전구체 (pyrimidine nucleotide precursors for treatment of systemic inflammation and iflammatory hepatitis)
KR950704342A (ko) 전신 염증(systemic inflammation) 및 염증성 간염(inflammatory hepatitis) 치료용 피리미딘 누클레오티드 전구체(pyrimindine nucleotide precursor)
US5726302A (en) Water soluble adenosine kinase inhibitors
DE69720811T2 (de) L-Ribavirin und dessen Verwendung
US5756478A (en) Method for reducing toxicity of D-nucleoside analogs with L-nucleosides
KR900015742A (ko) 항 비루스 제
ATE478886T1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
DE69706642D1 (de) Pyridylfuran- und Pyridylthiphenderivate und deren pharmazeutische Verwendung
MY140819A (en) Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
RU2011139180A (ru) Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции
EA200601591A1 (ru) Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
ATE165004T1 (de) Ematiomerenreine beta-d-dioxolane nucleoside mit selektiver antihepatitis b-virus wirkung
HUP0401291A2 (hu) 4'-helyettesített nukleozidok
IL273398B2 (en) History of 4'-fluoro-2'-methyl-modified nucleosides as inhibitors of HCV RNA replication
WO2005025501A3 (en) Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer
Lynch et al. Treatment of mouse neoplasms with high doses of tubercidin
KR950016754A (ko) 퀴녹살린 및 누클레오사이드를 포함하는 배합제제
KR880007080A (ko) 제약학적 생성물
JP2002515892A (ja) サイトカインが関係する疾患治療法
RU2007123607A (ru) Противоопухолевые комбинации, содержащие агент, ингибирующий vegf, и 5fu или одно из его производных
DE68904491T2 (de) Verwendung von adenosinderivaten zur herstellung von arzneimitteln mit immunstimulierender wirkung.
WO2003061568A3 (en) Methods and therapeutic compositions in the treatment of advanced cancer
EP0079054A1 (en) Enhancer of antitumor effect
KR920019362A (ko) 디데옥시 아데노신 및 아데노신 데아미나제 억제물질을 포함하는, 항-hiv활성을 지닌 치료학적 조성물
KR20070015642A (ko) ３-β-Ｄ-리보푸라노실티아졸로[４,５-ｄ]피리디민누클레오시드 및 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20081105

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20091115

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20091115

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000